British Columbia Covers Tumor Treating Fields Therapy for Glioblastoma Patients

Canada's first province to provide reimbursement for innovative cancer treatment

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Novocure announced that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma, an aggressive form of brain cancer. British Columbia is the first Canadian province to provide coverage for this innovative therapy following an assessment and reimbursement recommendation by Canada's Drug Agency.

Why it matters

Glioblastoma is one of the most deadly forms of cancer, with limited treatment options. The coverage of TTFields therapy in British Columbia means more patients will have access to a treatment that has the potential to extend their survival. This milestone represents progress in making innovative cancer therapies available to patients across Canada.

The details

TTFields therapy is a non-invasive treatment that uses electric fields to disrupt cancer cell division and growth. It was approved by Health Canada in 2022 for the treatment of newly diagnosed and recurrent glioblastoma. Prior to this announcement, TTFields therapy was only available to glioblastoma patients in Canada through private insurance or out-of-pocket payment. The new coverage in British Columbia will make this treatment more accessible to eligible patients.

  • TTFields therapy was approved by Health Canada in 2022 for the treatment of newly diagnosed and recurrent glioblastoma.
  • Novocure announced the coverage in British Columbia on February 24, 2026.

The players

Novocure

A global oncology company that developed and commercialized Tumor Treating Fields therapy.

BC Cancer

The cancer agency of British Columbia, Canada, that will provide coverage for TTFields therapy for eligible glioblastoma patients.

Lamia Kalfane

Country Manager, Novocure Canada.

Dr. Justin Oh

Radiation Oncologist, BC Cancer Vancouver.

Anita Angelini

Vice-Chair, Brain Cancer Canada.

Got photos? Submit your photos here. ›

What they’re saying

“Glioblastoma is one of the most aggressive cancers, and treatment options for this disease are limited. The newly announced coverage in British Columbia for Tumor Treating Fields therapy means more patients will have access to a treatment option that may potentially extend their survival.”

— Lamia Kalfane, Country Manager, Novocure Canada

“Access to treatment options is a priority when treating aggressive cancers. The addition of Tumor Treating Fields therapy as a covered treatment for eligible patients means we will be able to have more meaningful and robust discussion about available and approved treatment options for this tumor, framed within each patient's clinical circumstances and personal values.”

— Dr. Justin Oh, Radiation Oncologist, BC Cancer Vancouver

“When you are up against the relentless progression of brain cancer, a therapy that has met safety and efficacy standards, and has the potential to extend life is profound. Brain Cancer Canada congratulates BC Cancer and Novocure for their work to bring Tumor Treating Fields therapy to patients. Brain Cancer Canada continues to advocate for equitable access to treatment for patients in every province and territory across Canada.”

— Anita Angelini, Vice-Chair, Brain Cancer Canada

What’s next

Novocure remains committed to partnering with other provincial healthcare systems in Canada to ensure more eligible patients can access TTFields therapy.

The takeaway

The coverage of Tumor Treating Fields therapy in British Columbia represents a significant step forward in making innovative cancer treatments more accessible to patients in Canada. This milestone highlights the importance of collaboration between healthcare providers, patient advocates, and biopharmaceutical companies to improve outcomes for those battling aggressive forms of cancer.